Grossman et al. reported that patients with a CD4-positive lymphocyte count of less than 200 cells/mm3 at 2 months after initiating therapy for high-grade gliomas had a poor prognosis, and that the cause of the poor prognosis was tumor progression rather than infection. This evidence concerns the gene CD4 and neoplasm.